BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18796631)

  • 1. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
    Hallaert DY; Jaspers A; van Noesel CJ; van Oers MH; Kater AP; Eldering E
    Blood; 2008 Dec; 112(13):5141-9. PubMed ID: 18796631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
    Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM
    Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
    Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
    Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Sharma A; Singh K; Mazumder S; Hill BT; Kalaycio M; Almasan A
    Cell Death Dis; 2013 May; 4(5):e628. PubMed ID: 23681223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
    Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
    Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
    Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
    Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
    Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ
    Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM; Cosimo E; Leach MT; Michie AM
    Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
    Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
    Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
    Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
    J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
    Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
    Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
    Thomas A; Pepper C; Hoy T; Bentley P
    Leuk Lymphoma; 2004 May; 45(5):997-1008. PubMed ID: 15291360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
    Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
    Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.